This is a comment of an institutional broker for another company :
"We believe cancellation of the FDA Ad Com for Ingrezza in TD was a favorable event for NBIX. The FDA's comment that it was "no longer needed" bolsters our confidence in the Ingrezza TD NDA and, in our view, outweighs the Ph2 T-Forward study of Ingrezza in adults with Tourette Syndrome (TS) which failed to meet its primary endpoint"
Why should the same decision be bearish for Portola?
As I honestly haven't understood if it's a good or bad news I would like to hear also the "other side of the moon"
Thanks in advance
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM